Table 5

HR (95% CI) for self-harm during 6 months’ follow-up in users of varenicline versus NRT, adjusted for an unmeasured binary confounder with a HR of 3

P0/ P10.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
0.00.78 (0.37 to 1.63)0.94 (0.44 to 1.96)1.09 (0.52 to 2.28)1.25 (0.59 to 2.61)1.4 (0.67 to 2.93)1.56 (0.74 to 3.26)1.72 (0.81 to 3.59)1.87 (0.89 to 3.91)2.03 (0.96 to 4.24)2.18 (1.04 to 4.56)2.34 (1.11 to 4.89)
0.10.65 (0.31 to 1.36)0.78 (0.37 to 1.63)0.91 (0.43 to 1.9)1.04 (0.49 to 2.17)1.17 (0.56 to 2.45)1.3 (0.62 to 2.72)1.43 (0.68 to 2.99)1.56 (0.74 to 3.26)1.69 (0.8 to 3.53)1.82 (0.86 to 3.8)1.95 (0.93 to 4.08)
0.20.56 (0.26 to 1.16)0.67 (0.32 to 1.4)0.78 (0.37 to 1.63)0.89 (0.42 to 1.86)1 (0.48 to 2.1)1.11 (0.53 to 2.33)1.23 (0.58 to 2.56)1.34 (0.63 to 2.79)1.45 (0.69 to 3.03)1.56 (0.74 to 3.26)1.67 (0.79 to 3.49)
0.30.49 (0.23 to 1.02)0.59 (0.28 to 1.22)0.68 (0.32 to 1.43)0.78 (0.37 to 1.63)0.88 (0.42 to 1.83)0.98 (0.46 to 2.04)1.07 (0.51 to 2.24)1.17 (0.56 to 2.45)1.27 (0.6 to 2.65)1.37 (0.65 to 2.85)1.46 (0.69 to 3.06)
0.40.43 (0.21 to 0.91)0.52 (0.25 to 1.09)0.61 (0.29 to 1.27)0.69 (0.33 to 1.45)0.78 (0.37 to 1.63)0.87 (0.41 to 1.81)0.95 (0.45 to 1.99)1.04 (0.49 to 2.17)1.13 (0.53 to 2.35)1.21 (0.58 to 2.54)1.3 (0.62 to 2.72)
0.50.39 (0.19 to 0.82)0.47 (0.22 to 0.98)0.55 (0.26 to 1.14)0.62 (0.3 to 1.3)0.7 (0.33 to 1.47)0.78 (0.37 to 1.63)0.86 (0.41 to 1.79)0.94 (0.44 to 1.96)1.01 (0.48 to 2.12)1.09 (0.52 to 2.28)1.17 (0.56 to 2.45)
0.60.35 (0.17 to 0.74)0.43 (0.2 to 0.89)0.5 (0.24 to 1.04)0.57 (0.27 to 1.19)0.64 (0.3 to 1.33)0.71 (0.34 to 1.48)0.78 (0.37 to 1.63)0.85 (0.4 to 1.78)0.92 (0.44 to 1.93)0.99 (0.47 to 2.07)1.06 (0.5 to 2.22)
0.70.33 (0.15 to 0.68)0.39 (0.19 to 0.82)0.46 (0.22 to 0.95)0.52 (0.25 to 1.09)0.59 (0.28 to 1.22)0.65 (0.31 to 1.36)0.72 (0.34 to 1.49)0.78 (0.37 to 1.63)0.85 (0.4 to 1.77)0.91 (0.43 to 1.9)0.98 (0.46 to 2.04)
0.80.3 (0.14 to 0.63)0.36 (0.17 to 0.75)0.42 (0.2 to 0.88)0.48 (0.23 to 1)0.54 (0.26 to 1.13)0.6 (0.28 to 1.25)0.66 (0.31 to 1.38)0.72 (0.34 to 1.5)0.78 (0.37 to 1.63)0.84 (0.4 to 1.76)0.9 (0.43 to 1.88)
0.90.28 (0.13 to 0.58)0.33 (0.16 to 0.7)0.39 (0.19 to 0.82)0.45 (0.21 to 0.93)0.5 (0.24 to 1.05)0.56 (0.26 to 1.16)0.61 (0.29 to 1.28)0.67 (0.32 to 1.4)0.72 (0.34 to 1.51)0.78 (0.37 to 1.63)0.84 (0.4 to 1.75)
1.00.26 (0.12 to 0.54)0.31 (0.15 to 0.65)0.36 (0.17 to 0.76)0.42 (0.2 to 0.87)0.47 (0.22 to 0.98)0.52 (0.25 to 1.09)0.57 (0.27 to 1.2)0.62 (0.3 to 1.3)0.68 (0.32 to 1.41)0.73 (0.35 to 1.52)0.78 (0.37 to 1.63)
  • This tables shows how the observed HR (diagonal line of cells with dotted border) would change in the presence of an unmeasured confounder with a HR of three and different combinations of prevalence rates among the user groups. P1/P0=prevalence of the unmeasured confounder among users of varenicline (P1) and NRT (P0). The cells filled with grey mark the situations in which varenicline would be associated with a statistically significant increased hazard of the event. These calculations are based on: Lin et al. Biometrics 1998;54:948–63 (equation 2.9).

  • NRT, nicotine replacement therapy.